PEDIATRICS Vol. 61 No. 5 May 1978, pp. 711-715
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabor, E.
Right arrow Articles by Wilbur, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabor, E.
Right arrow Articles by Wilbur, J.

Prevalence of Hepatitis B in a High-Risk Setting: A Serologic Study of Patients and Staff in a Pediatric Oncology Unit

Edward Tabor M.D.1, Robert J. Gerety M.D., Ph.D.1, Martin Mott M.B., M.R.C.P.1, and Jordan Wilbur M.D.1

1 Division of Blood and Blood Products, Bureau of Biologics, U.S. Food and Drug Administration, Bethesda, Maryland, and the Department of Pediatric, Children's Hospital at Stanford, Palo Alto, California

The prevalence of serologic markers for hepatitis B virus (HBV) among 188 patients and 158 employees in a pediatric oncology unit was evaluated. Evidence of past or present HBV infection was detected in 33 patients (18%) and in 25 employees (16%). The prevalence was higher among patients receiving chemotherapy (19%) than among those not receiving chemotherapy (7%). The prevalence of HBV serologic markers, while much higher than generally found among healthy children in the United States, was low compared to previously reported prevalences in such settings, and may reflect the use in recent years of blood and blood products screened by "third generation" methods (radioimmunoassay and reversed passive hemagglutination) for hepatitis B surface antigen and the use of all volunteer blood donors. This prevalence suggests that perhaps there is less urgent need for the use of hepatitis B immune globulin and hepatitis B vaccine (when it becomes available) in oncology units than had been anticipated from earlier data in oncology units.

Submitted on August 3, 1977
Accepted on August 31, 1977